Kumar Dharmarajan

Kumar Dharmarajan, MD, MBA, is an adjunct assistant professor at Yale School of Medicine and Chief Scientific Officer at Clover Health, a Medicare Advantage technology company. Previously a full-time Yale faculty member, he focuses on improving healthcare for older adults through research in hospital and post-acute care, particularly addressing readmissions and post-hospital vulnerability. He holds an AB from Harvard, MD/MBA from Columbia, and has leadership roles in the National Quality Forum and CMS-related initiatives.

Education:

• AB, Harvard College, Social Studies (2001)
• MD, Columbia University College of Physicians & Surgeons (2006)
• MBA, Columbia Business School (2006)
• Internship/Residency/Fellowships: Massachusetts General Hospital (2007–2014)

Research Interests: Dr. Dharmarajan’s work centers on optimizing care transitions for elderly patients, reducing hospital readmissions, and understanding post-hospital syndrome. His research has influenced CMS quality measures and explores intersections of cardiology, geriatrics, and healthcare policy. Key areas include:

• Post-acute care pathways
• Geriatric cardiology
• Health equity in hospital systems
• Clinical quality metrics development

Publications & Trends: His 15 most recent articles focus on hospital readmission prevention, post-hospital vulnerability, and CMS-driven quality improvements. Notable themes include analyzing disparities in healthcare access, device efficacy in heart failure, and COPD outcomes. These studies emphasize translational research to inform policy and clinical practice.

Awards & Recognition: While no specific awards are listed, his contributions to CMS measure development and National Quality Forum involvement highlight impactful work in healthcare systems.

Advising & Grants: Collaborates with researchers like Harlan Krumholz on CMS-funded projects. Maintains clinical practice in geriatrics and cardiology while leading Clover’s R&D for complex patient populations.

Labs/Teams: Engaged with Yale’s cardiovascular and geriatric research teams, though specific lab affiliations are not detailed.